CJC1295

Buy CJC-1295 Peptide | Proven Long-Acting GHRH Analogue for GH Axis Research | PrimaLab Peptide

CJC-1295 (DAC:GRF) is a synthetic tetrasubstituted analogue of growth hormone-releasing hormone with Drug Affinity Complex (DAC) technology — the albumin-binding modification that extends its half-life to several days and makes it the longest-acting GHRH research analogue available. Researchers who buy CJC-1295 peptide use it to investigate sustained GH axis activation, IGF-1 axis dynamics over extended observation windows, downstream somatotropic signalling, and the effects of prolonged GHRH receptor stimulation — research applications where the short half-life of native GHRH or shorter-acting analogues such as Sermorelin Acetate would require impractically frequent administration in in vivo research designs. PrimaLab Peptide supplies research-grade CJC-1295 at ≥99% purity, independently verified by Janoshik Analytical, with a full batch-specific Certificate of Analysis included with every order.

What Is CJC-1295 (with DAC)?

CJC-1295 is a synthetic tetrasubstituted analogue of GHRH(1-29) — the minimal active N-terminal fragment of endogenous GHRH — with four amino acid substitutions that improve stability and potency, plus the critical Drug Affinity Complex (DAC) modification that enables albumin binding in vivo.

Key structural features:

• Tetrasubstituted GHRH(1-29) base: Four amino acid modifications relative to native GHRH(1-29) (Sermorelin) improve DPP-IV resistance and receptor binding affinity
• DAC modification: A maleimidoproprionic acid-lysine side chain modification at position 29 enables covalent binding to cysteine-34 of serum albumin after administration — the DAC (“Drug Affinity Complex”) technology developed by ConjuChem. This albumin binding dramatically extends the half-life from minutes (native GHRH) to several days
• Molecular formula: C₁₆₅H₂₆₉N₄₇O₄₆ | MW: 3647.28 g/mol
• Also known as: DAC:GRF (Drug Affinity Complex: Growth Hormone-Releasing Factor)

Critical distinction for research design: CJC-1295 with DAC is a fundamentally different research compound from CJC-1295 without DAC (Modified GRF 1-29). The without-DAC version lacks the albumin-binding modification, has a half-life of ~30–60 minutes, and produces pulsatile GH release. The with-DAC version produces sustained, non-pulsatile GH elevation lasting several days. These are not interchangeable compounds — confirm which version your research protocol specifies before ordering. CJC-1295 without DAC is available as part of the CJC-1295 + Ipamorelin Blend.

A comprehensive review of GHRH analogue pharmacology is available through published PubMed research on CJC-1295.

CJC-1295 Research Applications

CJC-1295 with DAC’s extended half-life is its primary research-defining characteristic. This sustained GHRH receptor activation profile enables research applications that shorter-acting analogues cannot practically support:

• Sustained GH axis activation research: CJC-1295 with DAC produces multi-day GH elevation in in vivo research models, allowing study of sustained somatotropic axis activation and its downstream consequences — not achievable with native GHRH or shorter-acting analogues requiring very frequent administration
• IGF-1 axis sustained elevation research: Sustained GH elevation produces extended IGF-1 responses, allowing research into the downstream effects of prolonged IGF-1 axis activation on target tissues — frequently studied alongside IGF-1 LR3
• GHRH receptor pharmacology research: CJC-1295 with DAC provides a tool for studying receptor occupancy dynamics over extended time periods, receptor desensitisation kinetics, and the downstream signalling consequences of sustained vs. pulsatile GHRH receptor activation — with Sermorelin Acetate and the without-DAC version serving as comparators for pulsatile activation
• Comparative GHRH analogue research: CJC-1295 with DAC serves as the long-acting reference compound in studies systematically comparing GHRH analogue half-life effects on GH secretion patterns and downstream responses — compared against Sermorelin Acetate (~10–20 min), CJC-1295 without DAC (~30–60 min), and Tesamorelin (intermediate extended stability)
• GH and IGF-1 metabolic effects research: Sustained GH/IGF-1 elevation allows investigation of metabolic consequences including effects on protein synthesis, lipolysis, glucose metabolism, and body composition changes in research models
• Dual-pathway GH research: CJC-1295 with DAC is frequently studied in research alongside Ipamorelin for combined GHRH receptor and GHSR-1a agonism studies — see the CJC-1295 + Ipamorelin Blend (CJC-1295 without DAC version for pulsatile protocols)

Purity & Third-Party Testing

Every batch of CJC-1295 supplied by PrimaLab Peptide is independently tested by Janoshik Analytical:

• HPLC — quantitative purity confirmed at ≥99%
• Mass Spectrometry — molecular identity confirmation (MW: 3647.28 g/mol), verifying the tetrasubstituted GHRH(1-29) sequence and the DAC modification

The batch-specific COA is included with every order. The Janoshik report is tied to the specific batch you receive — not a generic certificate or a report from a different lot. Verify the batch number on your vial matches the COA before use in any research protocol.

Storage & Reconstitution

• Lyophilized (sealed): Store at −20°C, away from light and moisture. Stable up to 24 months sealed under correct conditions
• After reconstitution: Store at 4°C and use within 28–30 days. Do not re-freeze reconstituted solution
• Reconstitution: Use sterile Bacteriostatic Water (BAC Water). Add slowly down the inside vial wall — roll the vial gently, never shake or vortex. Allow full dissolution before use
• Light protection: Keep away from direct UV exposure during reconstitution and storage
• Freeze-thaw cycles: Avoid — reconstitute only the volume needed for your current research window. Aliquot before freezing if multiple uses are planned

Product Specifications

Peptide Name	CJC-1295 (with DAC)
Also Known As	DAC: GRF
Sequence	Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ + DAC modification
Molecular Formula	C₁₆₅H₂₆₉N₄₇O₄₆
Molecular Weight	3647.28 g/mol
Purity	≥99% (Janoshik HPLC + Mass Spectrometry verified)
Form	Lyophilized powder
Available Sizes	2mg, 5mg, 10mg
Storage (sealed)	−20°C, away from light and moisture — stable 24 months
Storage (reconstituted)	4°C, use within 28–30 days
Reconstitution	Bacteriostatic Water (BAC Water)
Testing Lab	Janoshik Analytical (independent third-party)
COA	Batch-specific — included with every order
Intended Use	Laboratory research purposes only

Frequently Asked Questions — CJC-1295 Peptide

What is CJC-1295 with DAC used for in research?

Researchers who buy CJC-1295 peptide (with DAC) use it to investigate sustained GHRH receptor-mediated GH axis activation over multi-day observation windows, IGF-1 axis dynamics during prolonged GH elevation, GHRH receptor occupancy and desensitisation kinetics, comparative GHRH analogue half-life effects on GH secretion patterns, and metabolic consequences of sustained GH/IGF-1 elevation in research models. Its extended half-life is its primary research-defining feature distinguishing it from all other GHRH analogues in PrimaLab Peptide’s catalog. Published research is available on PubMed.

What is the difference between CJC-1295 with DAC and without DAC?

This is the most important distinction for CJC-1295 research design. With DAC: the albumin-binding Drug Affinity Complex modification extends half-life to several days, producing sustained non-pulsatile GH elevation. Without DAC (Modified GRF 1-29): no albumin binding, half-life ~30–60 minutes, produces pulsatile GH release that more closely mimics natural endogenous GH pulsatility. Choose with-DAC for research requiring sustained GH axis activation over days; choose without-DAC (available in the CJC-1295 + Ipamorelin Blend) for research requiring physiological pulsatile GH dynamics and intact feedback loop research.

Is it legal to buy CJC-1295 for research?

In most jurisdictions, yes — for legitimate laboratory research purposes only. CJC-1295 is not approved for human use by the FDA or equivalent regulatory authorities and is sold strictly as a research compound. Researchers should follow all applicable local regulations when purchasing, handling, and using peptides in a laboratory setting. PrimaLab Peptide supplies CJC-1295 exclusively for research use.

Is CJC-1295 from PrimaLab Peptide independently tested?

Yes. Every batch is independently verified by Janoshik Analytical at ≥99% purity via HPLC and mass spectrometry identity confirmation (MW: 3647.28 g/mol). The batch-specific COA is included with every order — tied to the specific lot you receive, not a generic template. Verify the batch number on your vial against the COA before use.

How does CJC-1295 with DAC compare to Tesamorelin?

Both are long-acting GHRH analogues but use different stability-extension strategies and have different structural bases. Tesamorelin retains the complete 44-amino acid GHRH sequence with a trans-3-hexenoyl N-terminal modification for DPP-IV resistance — extending half-life moderately while preserving the full GHRH sequence. CJC-1295 with DAC uses the shorter tetrasubstituted GHRH(1-29) base with an albumin-binding DAC modification — extending half-life to several days through albumin binding rather than enzymatic protection. These different structural approaches produce distinct pharmacokinetic profiles and make both compounds useful comparators in GHRH analogue comparative research.

What peptides are commonly studied alongside CJC-1295 with DAC?

Researchers buying CJC-1295 peptide for sustained GH axis research frequently explore Ipamorelin (selective GHSR-1a agonist for complementary GH frequency modulation), Sermorelin Acetate (short-acting GHRH for comparative pulsatility research), Tesamorelin (intermediate stability GHRH analogue for comparative research), HGH (direct GHR activation reference), and IGF-1 LR3 (downstream GH axis effector). The CJC-1295 + Ipamorelin Blend (without-DAC version) is available for pulsatile dual-pathway GH research.

Related Research Peptides

Researchers buying CJC-1295 peptide for GH axis research frequently explore:

• Ipamorelin — selective GHSR-1a agonist for complementary GH secretion research
• CJC-1295 + Ipamorelin Blend — dual-pathway GH research stack (without-DAC version)
• Sermorelin Acetate — GHRH(1-29) for short-acting pulsatile GH research
• Tesamorelin — full GHRH analogue for visceral fat and metabolic GH research
• HGH (Somatropin) — recombinant growth hormone for direct GHR activation studies
• IGF-1 LR3 — downstream GH axis effector for GH/IGF-1 axis research

Browse our complete Growth Hormone Peptides category. Bulk researchers can apply for discounted rates through our Wholesale Portal. Reconstitute with BAC Water, available in our Accessories & Reconstitution Supplies section.

⚠️ For laboratory research use only. Not approved for human use by the FDA or any equivalent regulatory authority. Not a drug, supplement, or medical treatment. Researchers are solely responsible for compliance with all applicable local and international regulations governing the purchase, storage, and use of research peptides.